Updated Testing: Aminoglycoside-Induced Hearing Loss Panel (MT-RNR1 gene)

• Guideline driven:
  • This panel includes 3 high risk variants in MT-RNR1 associated with aminoglycoside induced hearing loss according to the Clinical Pharmacogenetics Implementation Consortium (CPIC) (m.1095T>C, m.1494C>T, and m.1555A>G)

• Impact to clinical care:
  • Aminoglycosides are widely used antibiotics known to have side effects including a risk of hearing loss. Individuals carrying one of three high risk variants in MT-RNR1 have an increased risk of aminoglycoside-induced hearing loss.
  • CPIC guideline recommends individuals with the high-risk MT-RNR1 variants should “avoid aminoglycosides unless the high risk of permanent hearing loss is outweighed by the severity of infection and safe or effective alternative therapies are not available”. 
• The MT-RNR1 gene, including the above risk variants, is included in our OtoSCOPE v9 panel

Methodology: Targeted Sanger sequencing of MT-RNR1 variants: m.1095T>C, m.1494C>T, and m.1555A>G

Turn around time: 3 weeks

Sample types accepted:

• 3-5cc EDTA whole blood
• 5 ug DNA, resuspended in at least 50 ul of DNA Elution Buffer
• Saliva (DNA Genotek, ORAGene Discover, OGR-500)
• Buccal swabs, at least 4 (DNA Genotek, OraCollect, OCD-100)

Contact MORL for any questions or concerns at MORL@uiowa.edu

Cost: $185

CPT: 81401

• MORL Testing Menu
• MORL Hearing Testing Requisition Form

The Clinical Diagnostics Service of the Molecular Otolaryngology and Renal Research Laboratories is a Joint Commission-approved CLIA-accredited diagnostic laboratory.